Panacos Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PANC research report →
Price Chart
About the company
Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans.
- CEO
- John R. Barr
- IPO
- 2005
- Employees
- 41
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on PANC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.37K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.03
- P/B
- 0.00
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 21678.89%
- Net Margin
- -20810.56%
- ROE
- -85.57%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $180.00K-36.6%
- Gross Profit
- $180.00K-36.6%
- Op Income
- $39.02M
- Net Income
- $-37,459,000+1.7%
- EPS
- $-0.70+6.7%
- OCF Growth
- -4.7%
- FCF Growth
- -3.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -58.99
- RSI (14)
- 52
- Avg Volume
- 144
No earnings-call transcripts are available for PANC yet.
- Free Float
- 99.9%
- Shares Outstanding
- 53.67M
- Float Shares
- 53.60M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 08 | Fischer Laurent | other | 15,000 |
| Jun 19, 08 | LERNER IRWIN | other | 15,000 |
| Jun 19, 08 | FLETCHER R JOHN | other | 15,000 |
| Jun 19, 08 | Savage Robert G. | other | 15,000 |
| Jun 19, 08 | LIMBER JOSEPH M | other | 15,000 |
| Apr 30, 08 | DUNTON ALAN W | buy | 100,000 |
| Apr 30, 08 | DUNTON ALAN W | other | 100,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 100,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 150,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 37,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PANC coverage
Recent articles, reports, and earnings notes.
No research on PANC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PANC report →